Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Operating Expenses (2016 - 2025)

Zevra Therapeutics' Operating Expenses history spans 11 years, with the latest figure at $23.0 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 6.14% year-over-year to $23.0 million; the TTM value through Dec 2025 reached $90.4 million, down 6.81%, while the annual FY2025 figure was $90.4 million, 6.81% down from the prior year.
  • Operating Expenses reached $23.0 million in Q4 2025 per ZVRA's latest filing, up from $20.4 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $52.7 million in Q4 2022 to a low of $4.2 million in Q3 2021.
  • Average Operating Expenses over 5 years is $18.8 million, with a median of $21.3 million recorded in 2024.
  • Peak YoY movement for Operating Expenses: soared 872.09% in 2022, then crashed 50.54% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $5.4 million in 2021, then skyrocketed by 872.09% to $52.7 million in 2022, then plummeted by 50.54% to $26.1 million in 2023, then fell by 6.14% to $24.5 million in 2024, then decreased by 6.14% to $23.0 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Operating Expenses are $23.0 million (Q4 2025), $20.4 million (Q3 2025), and $24.2 million (Q2 2025).